375 related articles for article (PubMed ID: 24297483)
1. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
[TBL] [Abstract][Full Text] [Related]
2. Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines.
Nishimura Y; Takiguchi S; Yoshioka K; Nakabeppu Y; Itoh K
Int J Oncol; 2012 Oct; 41(4):1520-30. PubMed ID: 22859339
[TBL] [Abstract][Full Text] [Related]
3. Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
Nishimura Y; Hyuga S; Takiguchi S; Hyuga M; Itoh K; Hanawa T
Int J Oncol; 2016 May; 48(5):1895-906. PubMed ID: 26983447
[TBL] [Abstract][Full Text] [Related]
4. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
[TBL] [Abstract][Full Text] [Related]
5. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Nishimura Y; Yoshioka K; Bereczky B; Itoh K
Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
[TBL] [Abstract][Full Text] [Related]
6. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
Nishimura Y; Bereczky B; Ono M
Histochem Cell Biol; 2007 May; 127(5):541-53. PubMed ID: 17361439
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
[TBL] [Abstract][Full Text] [Related]
8. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
9. Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.
Ogi S; Fujita H; Kashihara M; Yamamoto C; Sonoda K; Okamoto I; Nakagawa K; Ohdo S; Tanaka Y; Kuwano M; Ono M
Cancer Sci; 2013 May; 104(5):573-83. PubMed ID: 23360489
[TBL] [Abstract][Full Text] [Related]
10. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
11. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
13. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
14. [c-Met signaling pathway participating in the gefitinib resistance of different gene types of non-small cell lung cancer cells induced by HGF in vitro].
Xuan X; An C; Zhou C
Zhongguo Fei Ai Za Zhi; 2013 Sep; 16(9):464-9. PubMed ID: 24034993
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
16. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
17. A role for sorting nexin 2 in epidermal growth factor receptor down-regulation: evidence for distinct functions of sorting nexin 1 and 2 in protein trafficking.
Gullapalli A; Garrett TA; Paing MM; Griffin CT; Yang Y; Trejo J
Mol Biol Cell; 2004 May; 15(5):2143-55. PubMed ID: 14978220
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
19. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
